플라스미드 DNA CDMO 시장 규모, 점유율, 동향 분석 보고서 : 서비스별, 용도별, 제조 등급별, 제조 규모별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Plasmid DNA CDMO Market Summary

The global plasmid DNA CDMO market size was valued at USD 753.2 million in 2025 and is projected to grow from USD 892.8 million in 2026 to USD 3,094.4 million by 2033, at a CAGR of 19.4% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 43.6% in 2025. Market growth is driven by increasing demand for plasmid DNA in gene therapy, cell therapy, DNA vaccines, and other advanced biopharmaceutical applications, alongside the expansion of development pipelines and growing outsourcing of plasmid DNA development and manufacturing activities.

Moreover, the need for specialized capabilities in plasmid design, bacterial fermentation, downstream purification, formulation, and fill-finish services is increasing the demand for CDMO services. Technological advancements in microbial expression systems, fermentation optimization, purification processes, automation, and analytical testing are improving manufacturing efficiency, product quality, scalability, and batch consistency.

Furthermore, the gene and cell therapy industry has witnessed continued growth in recent years, supported by increasing development activities and advances in plasmid DNA technologies. The growing number of plasmid DNA-based applications across gene therapy, cell therapy, DNA vaccines, and other advanced biopharmaceutical indications is increasing demand for specialized development and manufacturing capabilities. These products require controlled plasmid design, microbial fermentation, purification, formulation, analytical characterization, and GMP-compliant manufacturing processes. Thus, the expansion of plasmid DNA development pipelines is expected to increase demand for specialized CDMO services in the coming years.

In addition, several pharmaceutical and biotechnology companies are increasingly outsourcing plasmid DNA development and manufacturing activities to specialized CDMOs due to technical expertise, specialized infrastructure, and capital requirements associated with in-house production. CDMOs provide plasmid design, process development, fermentation optimization, scale-up, GMP manufacturing, purification, analytical testing, formulation, and fill-finish services. This approach enables developers to access specialized manufacturing capabilities while reducing the need to establish dedicated production facilities. The trend is particularly relevant among emerging biotechnology companies progressing advanced therapy candidates through clinical development and requiring flexible, scalable manufacturing capacity.

Global Plasmid DNA CDMO Market Report Segmentation

This report forecasts revenue growth at the global, regional & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global plasmid DNA CDMO market report based on service, application, manufacturing grade, manufacturing scale, end use, and region:

• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Contract Development
  • Process Development & Optimization
  • Analytical Testing & Method Validation
  • Scale-up & Tech Transfer
• Contract Manufacturing
  • Clinical
  • Commercial
• Packaging and Labeling
• Storage & Logistics
• Regulatory Affairs
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Cell & Gene Therapy
• DNA Vaccines
• Gene Editing
• RNA / mRNA-related Applications
• Others
• Manufacturing Grade Outlook (Revenue, USD Million, 2021 - 2033)
• Preclinical / Engineering Grade
• Clinical GMP Grade
• Commercial GMP Grade
• Manufacturing Scale Outlook (Revenue, USD Million, 2021 - 2033)
• Small Scale (<100 g)
• Mid Scale (100 g - 1 kg)
• Large Scale (>1 kg)
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Biopharmaceutical Companies
• Cell & Gene Therapy Developers
• Academic & Research Institutes
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Sweden
  • Norway
  • Denmark
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Oman
  • Qatar

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Service
  • 1.2.2. Application
  • 1.2.3. Manufacturing Grade
  • 1.2.4. Manufacturing Scale
  • 1.2.5. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Top-Down Analysis
  • 1.7.3. Bottom-Up Approach
  • 1.7.4. Multivariate Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Plasmid DNA CDMO Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Technology Landscape
• 3.4. Pricing Model Analysis
• 3.5. Tariff Impact Analysis
• 3.6. Value Chain Analysis
  • 3.6.1. Supply Trends
  • 3.6.2. Demand Trends
• 3.7. Market Analysis Tools
  • 3.7.1. Porter's Five Forces Analysis
  • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Plasmid DNA CDMO Market: Service Estimates & Trend Analysis

• 4.1. Service Market Share, 2025 & 2033
• 4.2. Service Segment Dashboard
• 4.3. Plasmid DNA CDMO Market: Service Movement Analysis
• 4.4. Global Plasmid DNA CDMO Market Size & Trend Analysis, by Service, 2021 to 2033 (USD Million)
• 4.5. Contract Development
  • 4.5.1. Contract Development Market Estimates & Forecasts, 2021 to 2033 (USD Million)
  • 4.5.2. Process Development & Optimization
    • 4.5.2.1. Process Development & Optimization Market Estimates & Forecasts, 2021 to 2033 (USD Million)
  • 4.5.3. Analytical Testing & Method Validation
    • 4.5.3.1. Analytical Testing & Method Validation Market Estimates & Forecasts, 2021 to 2033 (USD Million)
  • 4.5.4. Scale-up & Tech Transfer
    • 4.5.4.1. Scale-up & Tech Transfer Market Estimates & Forecasts, 2021 to 2033 (USD Million)
• 4.6. Contract Manufacturing
  • 4.6.1. Contract Manufacturing Market Estimates & Forecasts, 2021 to 2033 (USD Million)
  • 4.6.2. Clinical
    • 4.6.2.1. Clinical Market Estimates & Forecasts, 2021 to 2033 (USD Million)
  • 4.6.3. Commercial
    • 4.6.3.1. Commercial Market Estimates & Forecasts, 2021 to 2033 (USD Million)
• 4.7. Packaging and Labeling
  • 4.7.1. Packaging and Labeling Market Estimates & Forecasts, 2021 to 2033 (USD Million)
• 4.8. Storage & Logistics
  • 4.8.1. Storage & Logistics Market Estimates & Forecasts, 2021 to 2033 (USD Million)
• 4.9. Regulatory Affairs
  • 4.9.1. Regulatory Affairs Market Estimates & Forecasts, 2021 to 2033 (USD Million)
• 4.10. Others
  • 4.10.1. Others Market Estimates & Forecasts, 2021 to 2033 (USD Million)

Chapter 5. Plasmid DNA CDMO Market: Application Estimates & Trend Analysis

• 5.1. Application Market Share, 2025 & 2033
• 5.2. Application Segment Dashboard
• 5.3. Global Plasmid DNA CDMO Market: Application Movement Analysis
• 5.4. Global Plasmid DNA CDMO Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.5. Cell & Gene Therapy
  • 5.5.1. Cell & Gene Therapy Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 5.6. DNA Vaccines
  • 5.6.1. DNA Vaccines Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 5.7. Gene Editing
  • 5.7.1. Gene Editing Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 5.8. RNA / mRNA-related Applications
  • 5.8.1. RNA / mRNA-related Applications Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 5.9. Others
  • 5.9.1. Others Market Estimates & Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Plasmid DNA CDMO Market: Manufacturing Grade Estimates & Trend Analysis

• 6.1. Manufacturing Grade Market Share, 2025 & 2033
• 6.2. Manufacturing Grade Platform Segment Dashboard
• 6.3. Global Plasmid DNA CDMO Market: Manufacturing Grade Movement Analysis
• 6.4. Global Plasmid DNA CDMO Market Size & Trend Analysis, by Manufacturing Grade, 2021 to 2033 (USD Million)
• 6.5. Preclinical / Engineering Grade
  • 6.5.1. Preclinical / Engineering Grade Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 6.6. Clinical GMP Grade
  • 6.6.1. Clinical GMP Grade Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 6.7. Commercial GMP Grade
  • 6.7.1. Commercial GMP Grade Market Estimates & Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Plasmid DNA CDMO Market: Manufacturing Scale Estimates & Trend Analysis

• 7.1. Manufacturing Scale Market Share, 2025 & 2033
• 7.2. Manufacturing Scale Segment Dashboard
• 7.3. Global Plasmid DNA CDMO Market: Manufacturing Scale Movement Analysis
• 7.4. Global Plasmid DNA CDMO Market Size & Trend Analysis, by Manufacturing Scale, 2021 to 2033 (USD Million)
• 7.5. Small Scale (<100 g)
  • 7.5.1. Small Scale (<100 g) Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 7.6. Mid Scale (100 g - 1 kg)
  • 7.6.1. Mid Scale (100 g - 1 kg) Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 7.7. Large Scale (>1 kg)
  • 7.7.1. Large Scale (>1 kg) Market Estimates & Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Plasmid DNA CDMO Market: End Use Estimates & Trend Analysis

• 8.1. End Use Market Share, 2025 & 2033
• 8.2. End Use Segment Dashboard
• 8.3. Plasmid DNA CDMO Market: End Use Movement Analysis
• 8.4. Global Plasmid DNA CDMO Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 8.5. Biopharmaceutical Companies
  • 8.5.1. Biopharmaceutical Companies Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 8.6. Cell & Gene Therapy Developers
  • 8.6.1. Cell & Gene Therapy Developers Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 8.7. Academic and Research Institutions
  • 8.7.1. Academic and Research Institutions Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 8.8. Others
  • 8.8.1. Others Market Estimates & Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Plasmid DNA CDMO Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Dashboard
• 9.2. Plasmid DNA CDMO Market: Regional Movement Analysis
• 9.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
• 9.4. North America
  • 9.4.1. North America Plasmid DNA CDMO Market Estimates & Forecasts, By Country, 2021 - 2033 (USD Million)
  • 9.4.2. U.S.
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Regulatory Framework
    • 9.4.2.3. U.S. Plasmid DNA CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.4.3. Canada
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Regulatory Framework
    • 9.4.3.3. Canada Plasmid DNA CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.4.4. Mexico
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Regulatory Framework
    • 9.4.4.3. Mexico Plasmid DNA CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 9.5. Europe
  • 9.5.1. Europe Plasmid DNA CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.5.2. UK
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Regulatory Framework
    • 9.5.2.3. UK Plasmid DNA CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.5.3. Germany
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Regulatory Framework
    • 9.5.3.3. Germany Plasmid DNA CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.5.4. France
    • 9.5.4.1. Key Country Dynamics
    • 9.5.4.2. Regulatory Framework
    • 9.5.4.3. France Plasmid DNA CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.5.5. Italy
    • 9.5.5.1. Key Country Dynamics
    • 9.5.5.2. Regulatory Framework
    • 9.5.5.3. Italy Plasmid DNA CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.5.6. Spain
    • 9.5.6.1. Key Country Dynamics
    • 9.5.6.2. Regulatory Framework
    • 9.5.6.3. Spain Plasmid DNA CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.5.7. Denmark
    • 9.5.7.1. Key Country Dynamics
    • 9.5.7.2. Regulatory Framework
    • 9.5.7.3. Denmark Plasmid DNA CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.5.8. Sweden
    • 9.5.8.1. Key Country Dynamics
    • 9.5.8.2. Regulatory Framework
    • 9.5.8.3. Sweden Plasmid DNA CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.5.9. Norway
    • 9.5.9.1. Key Country Dynamics
    • 9.5.9.2. Regulatory Framework
    • 9.5.9.3. Norway Plasmid DNA CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 9.6. Asia Pacific
  • 9.6.1. Asia Pacific Plasmid DNA CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.6.2. Japan
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Regulatory Framework
    • 9.6.2.3. Japan Plasmid DNA CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.6.3. China
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Regulatory Framework
    • 9.6.3.3. China Plasmid DNA CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.6.4. India
    • 9.6.4.1. Key Country Dynamics
    • 9.6.4.2. Regulatory Framework
    • 9.6.4.3. India Plasmid DNA CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.6.5. Australia
    • 9.6.5.1. Key Country Dynamics
    • 9.6.5.2. Regulatory Framework
    • 9.6.5.3. Australia Plasmid DNA CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.6.6. South Korea
    • 9.6.6.1. Key Country Dynamics
    • 9.6.6.2. Regulatory Framework
    • 9.6.6.3. South Korea Plasmid DNA CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.6.7. Thailand
    • 9.6.7.1. Key Country Dynamics
    • 9.6.7.2. Regulatory Framework
    • 9.6.7.3. Thailand Plasmid DNA CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 9.7. Latin America
  • 9.7.1. Latin America Plasmid DNA CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.7.2. Brazil
    • 9.7.2.1. Key Country Dynamics
    • 9.7.2.2. Regulatory Framework
    • 9.7.2.3. Brazil Plasmid DNA CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.7.3. Argentina
    • 9.7.3.1. Key Country Dynamics
    • 9.7.3.2. Regulatory Framework
    • 9.7.3.3. Argentina Plasmid DNA CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 9.8. Middle East and Africa
  • 9.8.1. Middle East and Africa Plasmid DNA CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.8.2. South Africa
    • 9.8.2.1. Key Country Dynamics
    • 9.8.2.2. Regulatory Framework
    • 9.8.2.3. South Africa Plasmid DNA CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.8.3. Saudi Arabia
    • 9.8.3.1. Key Country Dynamics
    • 9.8.3.2. Regulatory Framework
    • 9.8.3.3. Saudi Arabia Plasmid DNA CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.8.4. UAE
    • 9.8.4.1. Key Country Dynamics
    • 9.8.4.2. Regulatory Framework
    • 9.8.4.3. UAE Plasmid DNA CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.8.5. Kuwait
    • 9.8.5.1. Key Country Dynamics
    • 9.8.5.2. Regulatory Framework
    • 9.8.5.3. Kuwait Plasmid DNA CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.8.6. Oman
    • 9.8.6.1. Key Country Dynamics
    • 9.8.6.2. Regulatory Framework
    • 9.8.6.3. Oman Plasmid DNA CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.8.7. Qatar
    • 9.8.7.1. Key Country Dynamics
    • 9.8.7.2. Regulatory Framework
    • 9.8.7.3. Qatar Plasmid DNA CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Participant Overview
• 10.2. Company Market Position Analysis
• 10.3. Company Categorization
• 10.4. Strategy Mapping
• 10.5. Company Profiles/Listing
  • 10.5.1. Thermo Fisher Scientific
    • 10.5.1.1. Company overview
    • 10.5.1.2. Financial performance
    • 10.5.1.3. Service benchmarking
    • 10.5.1.4. Strategic initiatives
  • 10.5.2. Aldevron (Danaher)
    • 10.5.2.1. Company overview
    • 10.5.2.2. Financial performance
    • 10.5.2.3. Service benchmarking
    • 10.5.2.4. Strategic initiatives
  • 10.5.3. Charles River Laboratories
    • 10.5.3.1. Company overview
    • 10.5.3.2. Financial performance
    • 10.5.3.3. Service benchmarking
    • 10.5.3.4. Strategic initiatives
  • 10.5.4. GenScript ProBio
    • 10.5.4.1. Company overview
    • 10.5.4.2. Financial performance
    • 10.5.4.3. Service benchmarking
    • 10.5.4.4. Strategic initiatives
  • 10.5.5. Lonza
    • 10.5.5.1. Company overview
    • 10.5.5.2. Financial performance
    • 10.5.5.3. Service benchmarking
    • 10.5.5.4. Strategic initiatives
  • 10.5.6. Catalent
    • 10.5.6.1. Company overview
    • 10.5.6.2. Financial performance
    • 10.5.6.3. Service benchmarking
    • 10.5.6.4. Strategic initiatives
  • 10.5.7. AGC Biologics
    • 10.5.7.1. Company overview
    • 10.5.7.2. Financial performance
    • 10.5.7.3. Service benchmarking
    • 10.5.7.4. Strategic initiatives
  • 10.5.8. WuXi AppTec
    • 10.5.8.1. Company overview
    • 10.5.8.2. Financial performance
    • 10.5.8.3. Service benchmarking
    • 10.5.8.4. Strategic initiatives
  • 10.5.9. Kaneka Eurogentec
    • 10.5.9.1. Company overview
    • 10.5.9.2. Financial performance
    • 10.5.9.3. Service benchmarking
    • 10.5.9.4. Strategic initiatives
  • 10.5.10. Richter-Helm BioLogics
    • 10.5.10.1. Company overview
    • 10.5.10.2. Financial performance
    • 10.5.10.3. Service benchmarking
    • 10.5.10.4. Strategic initiatives